Evidence map›Paper›PMID 32238663›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.

Yumi Aoyama, Yusuke Ushio, Takashi Yokoyama, Sekiko Taneda, Shiho Makabe, Miki Nishida, Shun Manabe, Masayo Sato, Hiroshi Kataoka, Ken Tsuchiya and 2 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yumi AoyamaDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Yusuke UshioDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Takashi YokoyamaDepartment of Clinical Laboratory Medicine, Tokyo Women's Medical University Hospital, Japan.
Sekiko TanedaDepartment of Pathology, Tokyo Women's Medical University, Japan.
Shiho MakabeDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Miki NishidaDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Shun ManabeDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Masayo SatoDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Hiroshi KataokaDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Ken TsuchiyaDepartment of Blood Purification, Tokyo Women's Medical University, Japan.
Kosaku NittaDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Toshio MochizukiDepartment of Nephrology, Tokyo Women's Medical University, Japan.
Tokyo Women's Medical University · JPTokyo Women's Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mulberry cells are often present in the urinary sediments of patients with Fabry disease (FD). We herein report two patients with FD undergoing enzyme replacement therapy (ERT). A 41-year-old man was diagnosed based on lack of α-galactosidase A activity. ERT was subsequently administered. A 40-year-old woman was diagnosed based on urinary Mulberry cells and genetic testing, and ERT was initiated. While the renal function of the male patient deteriorated, the Mulberry cells disappeared in the female patient after ERT was administered. The detection of urinary Mulberry cells can contribute to the diagnosis as well as serve as a biomarker for the response to treatment.

Indexed as

Enzyme Replacement TherapyAdultalpha-GalactosidaseBiomarkersFabry DiseaseFemaleGenetic TestingHumansMaleMicroscopy, ElectronPodocytesUrinealpha-GalactosidaseBiomarkersenzyme replacement therapyFabry diseaseLyso-Gb3Mulberry bodyMulberry cellurinary sediment

Identifiers

PMID32238663
PMCPMC7184092
OpenAlexW3014266376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.